Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Can the efficacy of one drug be influenced by another?

Michael Atkins, MD, from the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discusses drug combinations in the treatment of melanoma at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The ECOG-ACRIN 6134 study (NCT02224781) investigated dabrafenib plus trametinib followed by ipilimumab plus nivlumab, and vice versa. This study will determine whether the efficacy of one treatment is influenced by another. Studies looking at other aspects of this combination are also being carried out.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.